key: cord-0736397-4dowkeqq
authors: Iroh Tam, Pui-Ying
title: Approach to Common Bacterial Infections: Community-Acquired Pneumonia
date: 2013-01-12
journal: Pediatr Clin North Am
DOI: 10.1016/j.pcl.2012.12.009
sha: 9cf61f4d78ff84620ff376cf2b9b70402d805939
doc_id: 736397
cord_uid: 4dowkeqq

Community-acquired pneumonia (CAP) occurs more often in early childhood than at almost any other age. Many microorganisms are associated with pneumonia, but individual pathogens are difficult to identify, which poses problems in antibiotic management. This article reviews the common as well as new, emerging pathogens, as well as the guidelines for management of pediatric CAP. Current guidelines for pediatric CAP continue to recommend the use of high-dose amoxicillin for bacterial CAP and azithromycin for suspected atypical CAP (usually caused by Mycoplasma pneumoniae) in children.

A substantial proportion of CAP is mixed bacterial and viral infections; overdiagnosis of mild to moderate CAP can lead to overtreatment. The difficulty in differentiating between bacterial and viral pneumonia often leads to unnecessary antibiotic use. Current guidelines by the Pediatrics Infectious Diseases Society (PIDS) and the Infectious Diseases Society of America (IDSA) recommend amoxicillin (90 mg/kg/d orally in 2 doses) as the primary therapy for presumed bacterial pneumonia and azithromycin (10 mg/kg on day 1, followed by 5 mg/kg once daily on days 2-5) as the primary therapy for presumed atypical pneumonia in children younger than 5 years or aged 5 years or older. For children aged 5 years or older with presumed bacterial CAP who do not have clinical, laboratory, or radiographic evidence that distinguish bacterial CAP from atypical CAP, PIDS/IDSA guidelines note that a macrolide can be added to the b-lactam antibiotic. Much of the pediatric CAP guidelines is based on evidence of poor to moderate quality, and there many gaps in the evidence remain.

There are 2 main challenges in the diagnosis of CAP: the first is the definition of CAP, particularly in young children, in whom bacterial and viral infections can occur with similar frequencies, and in whom overdiagnosis of mild symptoms and signs may lead to unnecessary antibiotic use; the second is the identification of a causative pathogen, which is frequently impractical and inadequate in children, and in whom the failure to isolate an organism can result in unnecessary antibiotic use. These problems affect the management of CAP, and lead to emergence of resistance as a result of overtreatment. Management decisions are complicated because there are few randomized controlled trials in children that evaluate different antibiotic therapies and treatment duration. Although guidelines exist, they are often based on poorquality evidence.

The challenge for the general pediatrician is to recognize lower respiratory tract illness, to refer for hospitalization when it is severe, and to appropriately treat with antibiotics if a bacterial pneumonia is suspected. This review focuses on practical issues of clinical relevance for the general pediatrician, including what to elicit from the patient history and examination, keeping in mind not only the infections that are commonly seen but also emerging infectious diseases and those that are less frequently seen but that are severe when they occur.

The first key clinical issue is to diagnose CAP in children, and then determine which pathogen is responsible. There are discrepant definitions of CAP depending on whether the consideration is epidemiologic, which has more sensitive criteria, or regulatory, which is more specific ( Table 1) . Causative agents in children have been difficult to identify; however, clues in the history may help point toward certain infectious pathogens ( Table 2 ). The cause of pediatric pneumonia is usually based on age, because that is the best predictor available ( Table 3) .

Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) have been characterized as 2 bacteria predominately responsible for cases of fatal pneumonia in children. 1 However, widespread introduction of Hib and pneumococcal conjugate vaccines has led to significant declines, especially of Hib, although Streptococcus pneumoniae is still the predominant bacteria isolated from bacterial CAP in children. There is increasing recognition of the prevalence of mixed bacterial and viral infections, which have been documented in 23% to 33% of cases of pneumonia. [2] [3] [4] Atypical organisms (eg, Mycoplasma pneumoniae, Chlamydia pneumoniae) account for up to a third of cases. 5, 6 A new Chlamydia-like organism, Simkania negevensis, has been associated with bronchiolitis and pneumonia in children, 7 and has also been 

Identify bacteria in culture of sputum or gastric aspirates, with positive tuberculin skin test or interferon g release assay (continued on next page) 

with 59% in those older than 2 years. 4, 9 Viruses account for 30% to 67% of pediatric CAP, with influenza A, respiratory syncytial virus (RSV), and parainfluenza virus (PIV) 1, 2, and 3 most commonly identified. 4 A study by Singleton and colleagues 10 recovered respiratory viruses from 90% of Alaskan children younger than 3 years hospitalized with respiratory infections. In that case-control study of 865 children, RSV, PIV, human metapneumovirus (hMPV), and influenza were significantly more common in hospitalized cases than control children, but rhinovirus, adenovirus, and coronavirus were not. The high occurrence of asymptomatic carriage, such as in up to a third of asymptomatic children harboring rhinovirus, complicates the frequent detection of these respiratory viruses [10] [11] [12] ; the causative nature of many respiratory viruses in pneumonia, particularly ones identified by sensitive new molecular diagnostics, remain unclear. However, rhinovirus identification has been associated with bronchiolitis, asthma, and wheezing. 13, 14 hMPV, isolated in 2001, 15 has been recovered in 3.8% to 8.3% of isolates of nasopharyngeal and throat specimens of hospitalized children or children with CAP. 16, 17 Human bocavirus, first described in 2005, has been detected in up to 19% of clinical samples, mainly in infants and young children 18 ; its detection in serum and stool suggests that the virus may cause systemic disease. 18 In 2007, WU and KI polyomaviruses were detected in the respiratory tract samples of adults and children, 19, 20 and subsequently shown to be present in respiratory secretions in patients with acute respiratory illness. 21, 22 Severe acquired respiratory syndrome (SARS)-associated coronavirus was the first novel coronavirus to be characterized among a succession of other novel coronaviruses that decade. [23] [24] [25] Using sensitive reverse transcription polymerase chain reaction (PCR) assays, Dominguez and colleagues 26 detected coronavirus RNAs in 5% of pediatric respiratory specimens, and 41% of coronavirus-positive patients had evidence of a lower respiratory tract infection. Twenty-six percent of that group presented with vomiting or diarrhea, and 8% with meningoencephalitis or seizures, which suggests that coronavirus may have more systemic involvement than previously believed. Fungal pathogens such as Histoplasma, Coccidioides, Blastomyces, and Cryptococcus can cause pneumonia the immunocompromised patient population and may cause clinical illness in immunocompetent hosts, but usually not with the presentation of CAP. Blastomyces can cause prolonged fever and respiratory symptoms that mimic a prolonged CAP; however. Cryptococcus gattii, which can infect immunocompetent hosts, 27 has caused an increasing number of infections in the US Pacific Northwest since 2004 and has been detected in the southeastern United States. 28 The pathogen can cause cryptococcomas in the lungs, and in 1 report, 54% of infected patients had documented pneumonia. 27 Mycobacterium tuberculosis and nontuberculous mycobacteria can likewise cause CAP, but tend to be limited to people with high-risk exposures. Similarly, other high-risk exposures suggest specific causes, as outlined in Table 2 .

Symptoms (fever, chills, cough) of pneumonia can overlap significantly with a spectrum of conditions, such as bacterial sepsis or severe anemia, making differentiation between these diagnoses challenging. Signs such as crackles and egophony are more specific, but are often absent in clinical pneumonia in children. Chest radiography is considered the gold standard for confirmation of pneumonia, 29 but is also of questionable benefit in children, as discussed later. The limitation in diagnosis is reflected in the various definitions of pediatric CAP that exist (see Table 1 ), none of which is considered sufficiently sensitive or specific, and few of which have been validated in children. 30 For example, the World Health Organization (WHO) criteria for mild to moderate CAP are based on cough or breathing difficulties and age-adjusted tachypnea; such a definition places CAP with all other types of lower respiratory tract disease.

Clinical features in children with CAP vary with the age of the child, although none of them is very specific. Cevey-Macherel and colleagues 2 showed that more than a fifth of patients diagnosed with CAP as defined by WHO guidelines had completely normal breath sounds on admission, and auscultation was ruled to be poorly sensitive and specific in diagnosing WHO guideline-defined CAP in young children. However, WHO guidelines rely solely on respiratory rate and, using other criteria for a diagnosis of pneumonia or lower respiratory tract infection, respiratory rate has been shown to be less sensitive and specific in the first 3 days of illness. 31 In a study that defined pneumonia/lower respiratory tract infection as the presence of crepitations (crackles), wheeze, bronchial breathing, or chest radiograph (CXR) abnormalities, respiratory rates of less than 40 breaths/min were seen in 55% of children older than 35 months with a diagnosis of pneumonia. 32 Canadian guidelines regard oxygenation as a good indication of the severity of disease, 29 and oxygen saturation is recommended by the Infectious Diseases Society of America (IDSA) as a guide for referral of care and further diagnostic testing. 33 Clinical features do not reliably distinguish between viral, bacterial, and atypical pneumonias. 34, 35 Pneumococcal pneumonia has been associated with a history of fever and breathlessness and signs of tachypnea, indrawing, and toxic appearance, but these features can be indistinguishable from staphylococcal pneumonia at the beginning of illness. Similarly, mycoplasma pneumonia has been associated with cough, chest pain, and wheezing, symptoms being worse than the signs, as well as nonrespiratory symptoms such as arthralgia and headache, but studies have not successfully distinguished viral and bacterial CAP or between types of CAP by clinical Approach to Common Bacterial Infections signs alone. 36, 37 In addition, many children with CAP have mixed bacterial and viral infections. Mycoplasma pneumonia is more common in children aged 5 years or younger, and is typically characterized by slow progression, sore throat, low-grade fever and cough developing over 3 to 5 days. Although some children have more abrupt onset of symptoms or higher fevers, this pattern may help to distinguish it from pneumococcal or staphylococcal pneumonia, and influence treatment decisions, because there are no rapid laboratory tests that allow clear distinction between classic bacterial and atypical pneumonia.

Neither IDSA nor the British Thoracic Society (BTS) recommends CXRs for confirmation of suspected CAP in patients well enough to be treated in an outpatient setting. CXRs in children, unlike in adults with pneumonia, may not show any abnormalities, especially if taken at the onset of illness. 38 Beyond providing radiographic evidence of opacification, the use of a CXR is limited and has not been shown to correlate with clinical signs 39 or to help differentiate bacterial from viral pneumonia. 40 A prospective study in Switzerland enrolling 99 patients found that only 79% of patients had radiographic consolidation, with poor correlation between radiographic findings and diminished breath sounds, and no association with severity or cause of pneumonia. 2 A prospective study in the United Kingdom by Clark and colleagues 41 showed that lobar CXR changes were not associated with severity. In a study from Brazil, upper lobe involvement was shown to have 84% specificity and 65% positive predictive value for severity in children aged 1 year or younger hospitalized with CAP. 42 Whereas IDSA guidelines support a posteroanterior (PA) and lateral CXR in patients with suspected or documented hypoxemia or significant respiratory distress, and in those who have failed an initial course of antibiotic therapy, BTS guidelines do not recommend that a lateral CXR should be performed routinely. 43 This recommendation was based on a retrospective study from the United States that indicated that a frontal CXR was 100% sensitive and specific for lobar consolidation but would underdiagnose nonlobar infiltrates in 15% of cases. The investigators considered the clinical implications to be unclear. However, patients hospitalized for management of CAP (Box 1) should have both PA and lateral CXRs, to ensure that all infiltrates are detected and to assess for pleural effusion. Follow-up CXRs are unnecessary in children who recover uneventfully from an episode of CAP, but should be obtained in children who do not improve clinically and in those with progressive symptoms or clinical deterioration after 48 to 72 hours of antibiotic therapy. 33, 43 Most patients with bacterial pneumonia present with a lobar infiltrate (Fig. 1) . Interstitial infiltrates can be found in bacterial as well as viral and atypical pneumonia. 35 Mycoplasma pneumoniae pneumonia can have diffuse infiltrate radiologically out of proportion with clinical findings; lobar consolidation, atelectasis, nodular infiltration, and hilar adenopathy have also been described. Streptococcus pneumoniae pneumonia can present with round infiltrates (see Fig. 1B ), as can also be seen with other bacteria.

Microbiologic recovery sampled directly from the infected region of lung is the gold standard, although less invasive sampling methods are usually used to achieve a diagnosis (see Table 3 found this to be definitively useful in differentiating the cause or severity of CAP. 44, 45 Don and colleagues 46 studied 101 children and showed that an increase of 4 serum nonspecific inflammatory markers (WBC, CRP, ESR, PCT) was significantly associated with radiographic evidence of CAP; however, the role of these studies in the screening for bacterial and viral CAP was limited.

A study by Lahti and colleagues 47 involving children 6 months and older showed that inducing sputum production by inhalation of 5% hypertonic saline for 5 to 10 minutes and then aspirating or expectorating a sputum sample provided goodquality sputum specimens with 90% microbiological yield. However, the practicality of this relatively labor-intensive approach in a busy outpatient clinic is debatable. New molecular diagnostic tests have become available, particularly rapid antigen detection for respiratory viruses. Despite this development, one-quarter to one-third of patients still fail to yield an obvious cause. 48 

Indications of severe pediatric CAP 43 

Streptococcus pneumoniae is the most common bacterial pathogen in most studies but remains challenging to identify, because less than 10% of children with pneumonia are bacteremic and there are no definitive, noninvasive, and accurate tests. 3, 49 Urinary antigen tests for Streptococcus pneumoniae are not recommended by IDSA for the diagnosis of pneumococcal pneumonia in children, because false-positive tests are common and likely attributable to nasopharyngeal carriage. 50 Diagnosis of Mycoplasma pneumoniae infection can be made by testing for IgM to Mycoplasma pneumoniae in serum or plasma by enzyme-linked immunosorbent assay (ELISA), or by PCR testing of nasal, throat, or sputum specimens. PCR seems to detect more Mycoplasma infections than IgM ELISA testing, but a single standardized test has not been used across studies, so definitive data are difficult to obtain. Rapid IgM testing kits are being assessed, and may be a promising way to more rapidly detect Mycoplasma infection, but none has been validated as highly sensitive and specific in multiple studies. 33 

The main issue for a general pediatrician in management of suspected pediatric CAP is whether or not to treat with antibiotics. This decision is complicated because it is difficult to distinguish bacterial from viral pneumonia, and hence to decide whether antibiotics may be warranted. There are also few randomized controlled trials to guide antibiotic choice and duration. Because age is the best predictor of cause of pediatric pneumonia, guidelines for treatment are typically categorized by age and suspected pathogens. 33 BTS guidelines recommend that children with a clear clinical diagnosis of pneumonia should receive antibiotics, given that bacterial and viral pneumonia cannot be reliably differentiated. However, because viral pathogens are responsible for most of clinical disease in preschool-aged children with CAP, IDSA does not routinely recommend antimicrobial therapy for that group.

Streptococcus pneumoniae is the most prominent bacterial pathogen across all age groups, hence amoxicillin is recommended as first-line therapy for previously healthy, appropriately immunized patients. 33 Because the Hib vaccine offers no protection against nontypeable Haemophilus influenzae, there have not been alterations to choice of empiric antibiotic therapy for vaccinated children with suspected bacterial pneumonia. Atypical bacterial pathogens such as Mycoplasma pneumoniae are more prominent in school-aged children and older patients, and macrolide therapy is recommended for those with compatible findings, generally based on clinical findings. However, there are few high-quality data on the effectiveness of macrolide antibiotics in the treatment of children with Mycoplasma pneumonia, so the recommendation of treatment with a macrolide for this condition is listed as a weak recommendation in the PIDS/IDSA guidelines. 33 Bacterial-viral coinfections have been well documented to occur with influenza and Streptococcus pneumoniae, Staphylococcus aureus, and group A Streptococcus. 51 Hence, children with serious viral lower respiratory tract infections may still benefit from empiric therapy for bacterial agents. Adjunctive treatment with corticosteroids has been studied but has not shown proven benefit on outcomes. 52, 53 The summary PIDS/IDSA guidelines for CAP in children continue to recommend amoxicillin (90 mg/kg/d orally in 2 doses) as the primary therapy for presumed bacterial pneumonia and azithromycin (10 mg/kg on day 1, followed by 5 mg/kg once daily on days 2-5) as the primary therapy for presumed atypical pneumonia in children younger than 5 years or aged 5 years or older. For children aged 5 years or older with presumed bacterial CAP who do not have clinical, laboratory, or radiographic evidence to distinguish bacterial CAP from atypical CAP, PIDS/IDSA guidelines note that a macrolide can be added to the b-lactam antibiotic. 33 As noted earlier, there are no definitive clinical, laboratory, or radiographic findings that distinguish bacterial from atypical CAP, so the decision to use or add a macrolide remains based on an overall indication from the combined findings, rather than from a clearly defined set of criteria based on these findings.

Aside from influenza, there are no data from prospective, controlled studies for antiviral therapy against viruses associated with pediatric CAP. Adamantanes and neuraminidase inhibitors are effective against susceptible strains of influenza A, and neuraminidase inhibitors are effective for susceptible strains of influenza B. Because substantial genetic variation can occur in influenza from year to year, influenza virus strains can become resistant to either class of antiviral agents; most strains of influenza A isolated since the 2005 to 2006 season have been adamantine-resistant. 54 The recommended doses of antiviral agents for seasonal influenza were developed for fully susceptible strains 33 and evaluated in trials in which treatment was provided early, usually within 48 hours of onset of symptoms. 55 The degree of benefit provided by treatment after 48 hours of symptoms has not been defined.

Few studies have looked at the appropriate duration of antimicrobial therapy for CAP in children. Treatment courses of 10 days for b-lactams and 5 days for azithromycin have been best studied, although shorter courses have been studied showing no difference in acute cure or relapse rates between the groups. [56] [57] [58] Shorter courses are acknowledged to be just as effective, particularly for milder cases, although prolonged courses may be required for some pathogens, such as CA-MRSA. 59 Similarly, there are no randomized controlled studies evaluating the optimum time to switch from parenteral to oral therapy; hence IDSA and BTS guidelines do not provide a statement recommendation, although Canadian guidelines recommend switching from parenteral to oral therapy after 2 to 4 days if the patients are afebrile without complications. 29 

Antimicrobial-resistant Streptococcus pneumoniae has been a recognized problem since the 1990s. 60 The hope that the heptavalent pneumococcal conjugate vaccine Approach to Common Bacterial Infections (PCV7), which contains the 5 serotypes accounting for 89% of penicillin-resistant pneumococcal isolates in the United States, 61 would decrease antimicrobialresistant pneumococci in the community has seen marginal success. One longitudinal surveillance program showed penicillin-resistant isolates decreasing from 21.5% to 14.6%, but intermediate penicillin resistance increasing from 2.7% to 17.9%, after introduction of PCV7. 62 The effect of antibiotic resistance on clinical outcomes in children is less evident. Pneumococcal pneumonias that were penicillin-resistant or penicillin-sensitive were not associated with differences in outcome, hospital course, or complications. 63 No association between antimicrobial resistance and treatment failure has yet been shown in children. To minimize antimicrobial resistance, IDSA recommends limiting antibiotic exposure, using antibiotics with narrow spectrum activity and for shortest effective duration. 33 However none of these recommendations is based on strongquality evidence.

Fluoroquinolones are generally avoided in children younger than 18 years because of concerns for arthropathy, but experience with its use to treat children for a variety of serious infectious diseases has led to consensus statements that fluoroquinolones can treat specific infections in children safely and effectively, and may be considered as an alternative therapy in serious infectious diseases. 64 Bradley and colleagues 65 enrolled 738 children from 6 months to 16 years with CAP in a noninferiority trial, which showed similar cure rates with levofloxacin as with a comparator drug. Fifty-two percent of children treated with levofloxacin experienced 1 or more adverse events, compared with 53% in the comparator-treated children; musculoskeletal adverse events (arthralgia, myalgia) were experienced in 4% versus 3% in the comparator group who received current standard of care antibiotics. 65 None of these differences was statistically significant. In an era of emerging drug resistance, fluoroquinolones may be an effective alternative therapy in treating children with CAP.

Children with CAP who are on adequate therapy should clinically improve within 48 to 72 hours. If there is no improvement, possible complications to be considered include pleural effusions and empyema, necrotizing pneumonia, septicemia and metastatic infection (such as Staphylococcus aureus causing osteomyelitis or septic arthritis), and hemolytic-uremic syndrome. All of these complications require further investigation and possible hospitalization. Children with severe pneumonia, empyema, and lung abscess should be followed up after discharge until complete resolution clinically and on CXR. 43 Vaccines play a crucial part in prevention of pneumonia. Pertussis causes pneumonia in about 5% of all reported cases, which doubles to 11.8% of reported cases for those younger than 6 months. 66 Pneumonia complicating measles occurs in up to 27% to 77%, depending if the study was based in the community or hospital setting. 67 Half of measles-related pneumonias are caused by bacterial superinfection, and it contributes to 56% to 86% of all deaths in measles. 67 Influenza vaccines can prevent 87% of influenza-associated pneumonia hospitalizations, 68 including pneumococcal and CA-MRSA superinfection. 69, 70 Pneumococcal conjugate vaccines have decreased radiologically confirmed pneumonia by 20% to 37% and 67% to 87% of vaccine-serotype bacteremic pneumonia. 71, 72 The distribution of the 13-valent pneumococcal conjugate vaccine (PCV13) in 2010 may address the most common replacement serotypes that have been increasing since introduction of the 7-valent pneumococcal conjugate vaccine in the United States in 2000. 73 

Particularly, PCV13 contains the additional serotypes associated with empyema and necrotizing pneumonia, 74, 75 and thus it is hoped that the number of these complications will decrease. For high-risk infants, RSV-specific monoclonal antibody can decrease the risk of severe pneumonia and hospitalization.

Pneumonia occurs more often in early childhood than at any other age, with the exception of adults older than 75 years, and kills more children than any other disease worldwide. 76 The central clinical issue of CAP in children is that the diagnosis is typically not through microbiologic isolation, but rather through inference and deductions from clinical symptoms and signs, and supported by radiography and serum laboratory tests. This approach requires that the general pediatrician has a high level of suspicion and attempts to discern the cause as bacterial or viral, because this has implications for antimicrobial management.

CAP is changing, both in cause and in management approaches as more molecular diagnostics become available and well-performed trials are conducted. Despite this finding, although guidelines are available for patients with severe pediatric CAP, recommendations for mild to moderate cases, which constitute most cases seen by the general pediatrician, are based on evidence of poor to moderate quality. 77 This situation can lead to overtreatment 41 and, given the imprecise diagnostic methods available, unnecessary antibiotic treatment. There remain substantial gaps in the evidence for optimum management of pediatric CAP, from appropriate criteria for hospitalization to reference standards for identifying cases that need antibiotics, to what constitutes optimal antibiotic therapy. 78 

The pneumonia etiology research for child health project: a 21st century childhood pneumonia etiology study

Etiology of communityacquired pneumonia in hospitalized children based on WHO clinical guidelines

Etiology of community-acquired pneumonia in 254 hospitalized children

Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children

Role of Chlamydia pneumoniae and Mycoplasma pneumoniae as causative agents of community-acquired pneumonia in hospitalised children and adolescents

Role of Chlamydophila pneumoniae in children hospitalized for community

Simkania negevensis may be a true cause of community acquired pneumonia in children

High rate of Simkania negevensis among Canadian Inuit infants hospitalized with lower respiratory tract infections

Viruses in community-acquired pneumonia in children aged less than 3 years old: high rate of viral coinfection

Viral respiratory infections in hospitalized and community control children in Alaska

Frequent detection of respiratory viruses without symptoms: toward defining clinically relevant cutoff values

Rhinovirus transmission within families with children: incidence of symptomatic and asymptomatic infections

Human rhinovirus species associated with hospitalizations for acute respiratory illness in young US children

Human rhinoviruses in severe respiratory disease in very low birth weight infants

A newly discovered human pneumovirus isolated from young children with respiratory tract disease

Population-based incidence of human metapneumovirus infection among hospitalized children

Association of human metapneumovirus with radiologically diagnosed community-acquired alveolar pneumonia in young children

Human bocavirus: passenger or pathogen in acute respiratory tract infections?

Identification of a third human polyomavirus

Identification of a novel polyomavirus from patients with acute respiratory tract infections

WU polyomavirus in children with acute lower respiratory tract infections

Prevalence of human KI and WU polyomaviruses in children with acute respiratory tract infection in China

A novel coronavirus associated with severe acute respiratory syndrome

Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

Detection of four human coronaviruses in respiratory infections in children: a one-year study in Colorado

Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen

Cryptococcus gattii: an emerging fungal pathogen in the southeastern United States

A practical guide for the diagnosis and treatment of pediatric pneumonia

Defining pneumonia in critically ill infants and children

Diagnostic value of tachypnoea in pneumonia defined radiologically

Evaluation of simple clinical signs for the diagnosis of acute lower respiratory tract infection

The management of communityacquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America

Office pediatrics: current perspectives on the outpatient evaluation and management of lower respiratory infections in children

The value of clinical features in differentiating between viral, pneumococcal and atypical bacterial pneumonia in children

Differentiating bacterial from viral pneumonias in children

Problems in determining the etiology of community-acquired childhood pneumonia

Diagnosis and investigation of bacterial pneumonias

Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomised equivalency trial

Differentiation of bacterial and viral pneumonia in children

Children with pneumonia: how do they present and how are they managed?

Severity of childhood community-acquired pneumonia and chest radiographic findings

British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011

Non-specific host response markers in the differentiation between pneumococcal and viral pneumonia: what is the most accurate combination?

Serum procalcitonin concentrations in bacterial pneumonia in children: a negative result in primary healthcare settings

Differentiation of bacterial and viral communityacquired pneumonia in children

Induced sputum in the diagnosis of childhood community-acquired pneumonia

Pneumonia research to reduce childhood mortality in the developing world

Etiology of pneumonia and other common childhood infections requiring hospitalization and parenteral antimicrobial therapy. SE-TU Study Group

Evaluation of Binax NOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients

A role for Streptococcus pneumoniae in virus-associated pneumonia

Corticosteroid treatment of severe communityacquired pneumonia

Adjunct corticosteroids in children hospitalized with community-acquired pneumonia

Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States

Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial

Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial

Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial

Short-course versus long-course antibiotic therapy for non-severe community-acquired pneumonia in children aged 2 months to 59 months

Molecular analysis improves pathogen identification and epidemiologic study of pediatric parapneumonic empyema

Emergence of drug-resistant pneumococcal infections in the United States

The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States

Changing epidemiology of antimicrobialresistant Streptococcus pneumoniae in the United States

Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillinnonsusceptible Streptococcus pneumoniae

Committee on Infectious Diseases. The use of systemic fluoroquinolones

Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia

Pertussis-United States

Measles: not just another viral exanthem

Influenza vaccine effectiveness in healthy 6-to 21-month-old children during the 2003-2004 season

Seasonal invasive pneumococcal disease in children: role of preceding respiratory viral infection

Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

Severe necrotizing pneumonia in children

Pediatric parapneumonic empyema

Global, regional, and national causes of child mortality in 2008: a systematic analysis

Community-acquired pneumonia guidelines: much guidance, but not much evidence

Unsolved problems in the approach to pediatric community-acquired pneumonia

WHO guidelines on detecting pneumonia in children

World Health Organization. Technical bases for the WHO recommendations on the management of pneumonia in children at first-level health facilities

Evidence based paediatrics: review of BTS guidelines for the management of community acquired pneumonia in children

Community-acquired pneumonia in children